Early detection of Alzheimer’s disease-related changes in Parkinson’s disease and dementia with Lewy bodies could be made possible by monitoring the amyloid-β (Aβ) and phosphorylated tau (p-tau) proteins.
Leaving FDA, Califf is unapologetic — and warns of staff departures
In a wide-ranging interview, Robert Califf, the departing commissioner of the Food and Drug Administration, defended the FDA’s record under his leadership, praised the progress
January 8, 2025